With $80 million in funding from a list of high-profile backers, the startup is developing bifunctional antibodies that drag ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

The company intends to divest Roctavian and “remove it from our portfolio,” CEO Alexander Hardy said, following nearly three ...

For biopharma, reaching the right patients at the right time is essential for both clinical and commercial success. The right ...

The company intends to meet with the FDA to discuss results that showed a level of improvement on a marker of muscle ...

The startup, which has a pair of medicines in testing and others in development, aims to build the “ultimate coagulation ...

Clearance of Lynkuet provides a new alternative to hormone-based treatment for hot flashes and sets up a market battle with Astellas Pharma’s Veozah.

Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the ...

The French pharma’s overall vaccine sales declined 8% in the quarter, with a key driver being slower-than-usual uptake of flu ...

The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be ...

The deal, which Novartis expects can “unlock multibillion-dollar opportunities” in the years ahead, hands the company a group ...

Leaders and decision-makers facing the task of bringing new facilities online need construction partners who understand these ...